BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36880558)

  • 1. The clinical features, management and outcomes of lymphoma in pregnancy: A multicentre study by the Australasian Lymphoma Alliance.
    Di Ciaccio PR; Mills G; Shipton MJ; Campbell B; Gregory G; Langfield J; Greenwood M; McKeague S; Shanavas M; Eslick R; Kidson-Gerber G; Smallbone P; Tang C; Morris K; Bilmon I; Yannakou CK; Badoux X; Berkahn L; Farina S; Mason KD; Motum P; Goss K; Hamad N
    Br J Haematol; 2023 Jun; 201(5):887-896. PubMed ID: 36880558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of consolidative radiation therapy for patients with mediastinal diffuse large B-cell lymphoma in the rituximab era.
    Sert F; Kamer S; Saydam G; Anacak Y
    J Cancer Res Ther; 2018; 14(6):1397-1402. PubMed ID: 30488862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Mediastinal B-Cell Lymphoma in Children and Young Adults.
    Forlenza CJ; Chadburn A; Giulino-Roth L
    J Natl Compr Canc Netw; 2023 Mar; 21(3):323-330. PubMed ID: 36898366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
    Savage KJ; Al-Rajhi N; Voss N; Paltiel C; Klasa R; Gascoyne RD; Connors JM
    Ann Oncol; 2006 Jan; 17(1):123-30. PubMed ID: 16236753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy.
    Maggen C; Dierickx D; Cardonick E; Mhallem Gziri M; Cabrera-Garcia A; Shmakov RG; Avivi I; Masturzo B; Duvekot JJ; Ottevanger PB; O'Laughlin A; Polushkina E; Van Calsteren K; Woei-A-Jin FJSH; Amant F;
    Br J Haematol; 2021 Apr; 193(1):52-62. PubMed ID: 32945547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy.
    Pinnix CC; Osborne EM; Chihara D; Lai P; Zhou S; Ramirez MM; Oki Y; Hagemeister FB; Rodriguez AM; Samaniego F; Fowler N; Romaguera JE; Turturro F; Fayad L; Westin JR; Nastoupil L; Neelapu SS; Cheah CY; Dabaja BS; Milgrom SA; Smith GL; Horace P; Milbourne A; Wogan CF; Ballas L; Fanale MA
    JAMA Oncol; 2016 Aug; 2(8):1065-9. PubMed ID: 27227654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up.
    Zhou H; Xu-Monette ZY; Xiao L; Strati P; Hagemeister FB; He Y; Chen H; Li Y; Manyam GC; Li Y; Montes-Moreno S; Piris MA; Young KH
    Blood Cancer J; 2020 May; 10(5):49. PubMed ID: 32366834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of human immunodeficiency virus-associated Burkitt lymphoma and diffuse large B-cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance.
    Lim KJC; Di Ciaccio P; Polizzotto MN; Milliken S; Cochrane T; Goh Z; Shaw B; Perry E; Gilbertson M; Kermode W; Cheah CY; Latimer M; Hamad N; Ku M
    Br J Haematol; 2023 Jun; 201(5):865-873. PubMed ID: 36866733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 12. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
    Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
    Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
    Pavlovsky M; Cubero D; Agreda-Vásquez GP; Enrico A; Mela-Osorio MJ; San Sebastián JA; Fogliatto L; Ovilla R; Avendano O; Machnicki G; Barreyro P; Trufelli D; Villanova P
    JCO Glob Oncol; 2022 Mar; 8():e2100265. PubMed ID: 35486884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical Characteristics and Prognosis of 56 Lymphoma Patients with Mediastinal Masses].
    Yu H; Wang L; Zhu HY; Wu W; Liang JH; Yin H; Fan L; Li JY; Xu W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):495-499. PubMed ID: 32319385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma.
    Kim SJ; Yoon DH; Kang HJ; Hong JY; Lee HS; Oh SY; Shin HJ; Kong JH; Yi JH; Sakamoto K; Ko YH; Huh J; Lee SS; Takeuchi K; Shin DY; Suh C; Kim WS
    BMC Cancer; 2019 Nov; 19(1):1080. PubMed ID: 31707975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Moccia AA; Hitz F; Hoskins P; Klasa R; Power MM; Savage KJ; Shenkier T; Shepherd JD; Slack GW; Song KW; Gascoyne RD; Connors JM; Sehn LH
    Leuk Lymphoma; 2017 Feb; 58(2):324-332. PubMed ID: 27347845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component].
    Lin ZJ; Zha J; Yi SH; Li ZF; Ping LY; He XH; Yu HF; Zheng Z; Xu W; Chen FL; Xie Y; Chen BY; Zhang HL; Wang L; Ding KY; Li WY; Yang HY; Zhao WL; Qiu LG; Li ZM; Song YQ; Xu B
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):456-462. PubMed ID: 35968587
    [No Abstract]   [Full Text] [Related]  

  • 18. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
    Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
    Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study.
    Maggen C; Dierickx D; Lugtenburg P; Laenen A; Cardonick E; Shmakov RG; Bellido M; Cabrera-Garcia A; Gziri MM; Halaska MJ; Ottevanger PB; Van Calsteren K; O'Laughlin A; Polushkina E; Van Dam L; Avivi I; Vandenberghe P; Woei-A-Jin FJSH; Amant F;
    Lancet Haematol; 2019 Nov; 6(11):e551-e561. PubMed ID: 31564649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study.
    Morgenstern Y; Aumann S; Goldschmidt N; Gatt ME; Nachmias B; Horowitz NA
    Cancer Med; 2021 Dec; 10(24):8866-8875. PubMed ID: 34816617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.